Next Article in Journal
Light-Up RNA Aptamers and Their Cognate Fluorogens: From Their Development to Their Applications
Next Article in Special Issue
Autoimmunity and Gastric Cancer
Previous Article in Journal
Inhibition of Aquaporin-4 Improves the Outcome of Ischaemic Stroke and Modulates Brain Paravascular Drainage Pathways
Previous Article in Special Issue
Predicting the Functional Impact of CDH1 Missense Mutations in Hereditary Diffuse Gastric Cancer
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2018, 19(1), 47;

Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype

Immunopathology and Cancer Biomarkers, IRCCS CRO National Cancer Institute, 33081 Aviano, Italy
Medical Oncology, IRCCS, CRO National Cancer Institute, 33081 Aviano, Italy
Department of Medicine, School of Medical Oncology, University of Udine, 0432 Udine, Italy
SSD Oncology, Ospedale Civile Alghero, 07041 Alghero, Italy
Operative Unit of Pathology Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, 07100 Sassari, Italy
Institute of Biomolecular Chemistry, Cancer Genetics Unit, C.N.R., 07100 Sassari, Italy
Gastroenterology, IRCCS CRO National Cancer Institute, 33081 Aviano, Italy
Pathology, IRCCS CRO National Cancer Institute, 33081 Aviano, Italy
Medical Oncology Department, Santa Maria degli Angeli Hospital, 33170 Pordenone, Italy
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 28 November 2017 / Revised: 19 December 2017 / Accepted: 21 December 2017 / Published: 23 December 2017
(This article belongs to the Special Issue Molecular Features Distinguishing Gastric Cancer Subtypes)
Full-Text   |   PDF [1226 KB, uploaded 24 December 2017]   |  


The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a fraction of patients. The aim of this study was to improve knowledge of the HER2 and the E-cadherin alterations in the context of GC to characterize subtypes of patients that could better benefit from targeted therapy. An association between the P7-CDH1 haplotype, including two polymorphisms (rs16260A-rs1801552T) and a subset of HER2-positive mGC with better prognosis was observed. Results indicated the potential evaluation of CDH1 haplotypes in mGC to stratify patients that will benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding the HER2 and the E-cadherin interactions in vivo and in response to treatments. View Full-Text
Keywords: E-cadherin; CDH1; HER2; metastatic gastric cancer; rs16260; rs1801552 E-cadherin; CDH1; HER2; metastatic gastric cancer; rs16260; rs1801552

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Caggiari, L.; Miolo, G.; Buonadonna, A.; Basile, D.; Santeufemia, D.A.; Cossu, A.; Palmieri, G.; De Zorzi, M.; Fornasarig, M.; Alessandrini, L.; Canzonieri, V.; Lo Re, G.; Puglisi, F.; Steffan, A.; Cannizzaro, R.; De Re, V. Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. Int. J. Mol. Sci. 2018, 19, 47.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top